已收盘 05-15 16:00:00 美东时间
+0.090
+3.78%
今日重点评级关注:瑞杰金融:上调InflaRx评级至"强烈买入",目标价从7美元升至9美元;巴克莱:维持Orchestra BioMed Hldgs"超配"评级,目标价从12美元升至13美元
05-14 14:32
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从9美元升至11美元;康托·菲茨杰拉德:维持Artiva Biotherapeutics"超配"评级,目标价从10美元升至40美元
05-12 12:36
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
05-11 21:47
伟创力绩后暴涨近40%!宣布分拆云计算部门独立上市;NNE大涨27%,与超微电脑联手探索核能AI数据中心>>
05-07 19:09
Gainers GlucoTrack (NASDAQ:GCTK) stock increased by 39.7% to $1.02 during Wedn...
05-07 01:05
All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds
05-06 20:34
InflaRx N.V. on Tuesday said it had regained compliance with Nasdaq’s minimum bid price requirement, after its shares closed at or above $1.00 for 10 consecutive business days between April 13 and Apr...
04-28 19:53
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"),
04-28 19:33
今日重点评级关注:HC Wainwright & Co.:维持Century Therapeutics"买入"评级,目标价从2美元升至5美元;Oppenheimer:维持Climb Bio"跑赢大市"评级,目标价从10美元升至18美元
04-22 12:41